Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.

Chowdhury O., O'Sullivan J., Barkas N., Wang G., Buck G., Hamblin A., Tefferi A., Al-Ali HK., Barosi G., Devos T., Gisslinger H., Jiang Q., Kiladjian J-J., Mesa R., Passamonti F., Ribrag V., Schiller G., Vannucchi AM., Zhou D., McMullin MF., Zhong J., Gale RP., Mead AJ., RESUME trialists None.

DOI

10.1038/s41375-020-0979-6

Type

Journal article

Journal

Leukemia

Publication Date

04/2021

Volume

35

Pages

1197 - 1202

Keywords

Disease Management, Disease Susceptibility, Erythrocyte Transfusion, Humans, Mutation, Myeloproliferative Disorders, Primary Myelofibrosis, Spliceosomes, Thalidomide, Treatment Outcome

Permalink Original publication